Shanghai Fuhong Hanlin Biotechnology Co., Ltd. was established on February 24th, 20 10. The legal representative is Chen Qiyu, and the business scope of the company is: research and development of monoclonal antibody drugs (except the development and application of human stem cells and gene diagnosis and treatment technology), transfer of own technology, and provision of relevant technical services and technical consultation.
Fu Honghanlin is a biopharmaceutical platform under Fosun Pharma. Established by Fosun Pharma and overseas scientists on 20 10, focusing on the research and development of monoclonal antibody drugs. Fosun Pharma holds 53.3% of the shares of Fu Honghanlin, but Fu Honghanlin is a research and development enterprise without its own sales team, and its products are sold by Jiangsu Wanbang of Fosun Pharma. If the sales profit is calculated according to 1/3- 1/2, Fosun Pharma can get 70-75% of the profit of Fu Honghanlin Biopharmaceutical.